AbbVie Inc (ABBV)
203.55
-0.32
(-0.16%)
USD |
NYSE |
Nov 01, 16:00
203.53
-0.02
(-0.01%)
After-Hours: 20:00
AbbVie Enterprise Value: 417.06B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 417.06B |
| October 31, 2024 | 417.62B |
| October 30, 2024 | 413.44B |
| October 29, 2024 | 392.15B |
| October 28, 2024 | 392.56B |
| October 25, 2024 | 389.33B |
| October 24, 2024 | 392.51B |
| October 23, 2024 | 389.38B |
| October 22, 2024 | 390.94B |
| October 21, 2024 | 387.01B |
| October 18, 2024 | 391.11B |
| October 17, 2024 | 390.60B |
| October 16, 2024 | 393.94B |
| October 15, 2024 | 396.41B |
| October 14, 2024 | 403.11B |
| October 11, 2024 | 400.53B |
| October 10, 2024 | 400.81B |
| October 09, 2024 | 401.52B |
| October 08, 2024 | 398.44B |
| October 07, 2024 | 399.50B |
| October 04, 2024 | 400.70B |
| October 03, 2024 | 402.75B |
| October 02, 2024 | 405.17B |
| October 01, 2024 | 405.42B |
| September 30, 2024 | 406.34B |
| Date | Value |
|---|---|
| September 27, 2024 | 401.59B |
| September 26, 2024 | 396.48B |
| September 25, 2024 | 395.35B |
| September 24, 2024 | 399.33B |
| September 23, 2024 | 399.89B |
| September 20, 2024 | 399.25B |
| September 19, 2024 | 399.52B |
| September 18, 2024 | 398.32B |
| September 17, 2024 | 399.22B |
| September 16, 2024 | 403.25B |
| September 13, 2024 | 400.56B |
| September 12, 2024 | 400.23B |
| September 11, 2024 | 401.23B |
| September 10, 2024 | 409.64B |
| September 09, 2024 | 404.47B |
| September 06, 2024 | 399.13B |
| September 05, 2024 | 398.18B |
| September 04, 2024 | 405.51B |
| September 03, 2024 | 406.71B |
| August 30, 2024 | 404.27B |
| August 29, 2024 | 402.27B |
| August 28, 2024 | 402.66B |
| August 27, 2024 | 403.58B |
| August 26, 2024 | 406.27B |
| August 23, 2024 | 406.46B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.05B
Minimum
Mar 23 2020
417.62B
Maximum
Oct 31 2024
290.59B
Average
305.80B
Median
Oct 24 2023
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Johnson & Johnson | 400.99B |
| Eli Lilly and Co | 805.11B |
| Merck & Co Inc | 284.75B |
| Pfizer Inc | 221.03B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.561B |
| Revenue (Quarterly) | 14.46B |
| Total Expenses (Quarterly) | 10.55B |
| EPS Diluted (Quarterly) | 0.88 |
| Gross Profit Margin (Quarterly) | 70.87% |
| Profit Margin (Quarterly) | 10.80% |
| Earnings Yield | 1.41% |
| Operating Earnings Yield | 4.16% |
| Normalized Earnings Yield | 1.643 |